ADA/IFX-treated RA patients showed inhibition of a pro-inflammatory macrophage response and activation of an anti-inflammatory response, such as the factors SOCS-1, IL-10, CEBPβ, and c-MYC (9) (Figure 4A). This evidence concerns the gene CEBPB and rheumatoid arthritis.